Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 5,927 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: 14C-VX-407; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 66
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more

Conditions: Acne Vulgaris
Interventions: Isotretinoin, Tetracycline; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Squamous Cell Carcinoma, Neoplasia, Head and Neck Cancer
Interventions: High Resolution Microendoscopy (HRME), Proflavine hemisulfate; Device · Other
Lead sponsor: Sharmila Anandasabapathy, MD; Individual
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Any Solid Tumor or Lymphoma
Interventions: OSI-027; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Mucositis, Stomatitis
Interventions: phenylephrine solution; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cystic Fibrosis
Interventions: Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed; Other
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 3 Years to 18 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: DTG 50 mg, RPV 25 mg, DTG/RPV 50 mg/25 mg: Product Code AS, DTG/RPV 50 mg/25 mg: Product Code AM, DTG/RPV 50 mg/25 mg: Product Code AQ, DTG/RPV 50 mg/25 mg: Product Code AK, DTG/RPV 50 mg/25 mg: Product Code AR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Conditions: Age-related Macular Degeneration
Interventions: QA102, Placebo; Drug
Lead sponsor: Smilebiotek Zhuhai Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Covid19
Interventions: ADX-629, Placebo; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Major Depressive Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Little Rock, Arkansas • La Jolla, California • Santa Monica, California + 17 more

Conditions: Allergy
Interventions: Xolair (omalizumab); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Primary Brain Tumor, Brain Tumor, Recurrent
Interventions: Fluoxetine, Temozolomide; Drug
Lead sponsor: Duke University; Other
Eligibility: 24 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: San Diego, California • Stanford, California • New York, New York + 1 more

Conditions: Periodontal Disease
Interventions: Risedronate; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 40 Years to 80 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Benign Prostatic Hyperplasia
Interventions: LY500307, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Huntsville, Alabama • Anchorage, Alaska • Glendora, California + 37 more

Conditions: Healthy Volunteers
Interventions: levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metastatic Breast Cancer
Interventions: PMD-026, fulvestrant; Drug
Lead sponsor: Phoenix Molecular Designs; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: Gilbert, Arizona • Duarte, California • Irvine, California + 7 more

Conditions: Liver Disease
Interventions: sofosbuvir/ledipasvir, sofosbuvir, Ribavirin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: New York, New York • Dallas, Texas

Conditions: Dentin Sensitivity
Interventions: Potassium oxalate, Sodium fluoride, Placebo; Device · Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Head and Neck Cancer, Oral Mucositis
Interventions: Grape extract, Lortab, Fentanyl patch, mouthwash; Dietary Supplement · Drug
Lead sponsor: University of Louisville; Other
Eligibility: 20 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary Origin, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer, Oropharyngeal Cancer, HNSCC, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
Interventions: Cetuximab, Ficlatuzumab; Biological · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Tucson, Arizona • New Haven, Connecticut • Tampa, Florida + 3 more

Conditions: Heart Failure
Interventions: AMG 986; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Tustin, California • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Lymphoma
Interventions: forodesine hydrochloride; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 10
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Stanford, California + 7 more

Search by objective public record fields.

Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

Weekly Isotretinoin vs Tetracycline for Moderate Acne

Optical Imaging of Head and Neck Cancer

Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma

Safety of Phenylephrine for Oral Mucositis Prevention

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

A Safety and Efficacy Study of Xolair in Peanut Allergy

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Effect of Actonel on Periodontal Health of Postmenopausal Women

A Study in Men With Benign Prostatic Hyperplasia

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity

Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma